[1]CurrentPatentAssignee:H.LEEMOFFITTCANCERCENTER&RESEARCHINSTITUTE-WO2011/130740,2011,A2Locationinpatent:Page/Pagecolumn92-93
[2]Pireddu,Roberta;Forinash,KaraD.;Sun,NanN.;Martin,MathewP.;Sung,Shen-Shu;Alexander,Brian;Zhu,Jin-Yi;Guida,WayneC.;Schönbrunn,Ernst;Sebti,SaïdM.;Lawrence,NicholasJ.[MedChemComm,2012,vol.3,#6,p.699-709]
[1]CurrentPatentAssignee:H.LEEMOFFITTCANCERCENTER&RESEARCHINSTITUTE-WO2011/130740,2011,A2Locationinpatent:Page/Pagecolumn94
[2]Pireddu,Roberta;Forinash,KaraD.;Sun,NanN.;Martin,MathewP.;Sung,Shen-Shu;Alexander,Brian;Zhu,Jin-Yi;Guida,WayneC.;Schönbrunn,Ernst;Sebti,SaïdM.;Lawrence,NicholasJ.[MedChemComm,2012,vol.3,#6,p.699-709]
[1]MedChemComm,2012,vol.3,p.699-709
[1]Pireddu,Roberta;Forinash,KaraD.;Sun,NanN.;Martin,MathewP.;Sung,Shen-Shu;Alexander,Brian;Zhu,Jin-Yi;Guida,WayneC.;Schönbrunn,Ernst;Sebti,SaïdM.;Lawrence,NicholasJ.[MedChemComm,2012,vol.3,#6,p.699-709]
Title: Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).
Journal: MedChemComm 20120601
Title: Patel RA, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34.